Xiaoxiong Xiao

Prof. Dr. Xiaoxiong Xiao

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2022 in Frontiers in Medicine
Verified
Journal Article
Open access
RYRuolan Yuan
Ruolan Yuan
KLKangcheng Liu
Kangcheng Liu
YCYingjun Cai
Yingjun Cai
FHFei He
Fei He
XXXiaoxiong Xiao
Xiaoxiong Xiao
JZJing Zou
Jing Zou
Background: Body size (BS) is one of the risk factors for the development of many clinical diseases, but the relationship between BS and glaucoma is controversial. Herein, we try to use Mendelian randomization (MR) method to study BS causal association with glaucoma risk from the genetic level.Methods: The Body Size was determined through anthropometric traits (ATs), such as body mass index (BMI), waist-to-hip ratio adjusted by body mass index (WHRadjBMI), waist-to-hip ratio (WHR), and waist circumference (WC). Association of single nucleotide polymorphisms (SNPs) with each AT and glaucoma were determined individually from the aggregated data of the Genetic Investigation of Anthropometric Traits (GIANT) consortium and the FinnGen study summary data (8,591 cases with glaucoma and 210,201 controls). To explore the role of BS and glaucoma, a two-sample MR analysis was performed on genome-wide association study (GWAS) data. Besides, three MR methods [inverse variance weighted (IVW), Weighted median, and MR-Egger regression] were used to get the whole causal estimate for multiple instrumental SNPs.Results: BMI (OR = 1.20; 95% CI = 1.02–1.41; P = 0.03) and WC (OR = 1.32; 95% CI =1.04–1.69; P = 0.03) were associated with a risk of glaucoma. Besides, genetically predicted WHRadjBMI (OR = 1.10; 95% CI = 0.88–1.35; P = 0.43) and WHR (OR = 1.22; 95% CI = 0.93–1,572; P = 0.14) were not associated with glaucoma. No heterogeneity and directional pleiotropy were detected.Conclusion: The data of this study revealed that increased BMI and WC are potential risk factors for glaucoma, and WHRadjBMI and WHR are not associated with the occurrence of glaucoma.

6 September 2023 in Cellular Oncology
Verified
Journal Article
Closed access
PDF file
HWHaiqin Wang
Haiqin Wang
HWHaohui Wang
Haohui Wang
JCJiajing Chen
Jiajing Chen
PLPian Liu
Pian Liu
XXXiaoxiong Xiao
Xiaoxiong Xiao

26 September 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
SFSongshan Feng
Songshan Feng
XLXisong Liang
Xisong Liang
JLJing Li
Jing Li
ZWZeyu Wang
Zeyu Wang
HZHao Zhang
Hao Zhang
Quan ChengQuan Cheng
Quan Cheng
Immunogenic cell death (ICD) is a type of cell death that leads to the regulation and activation of the immune response, which is marked by the exposure and delivery of damage‐associated molecular patterns (DAMPs) in the tumor microenvironment. Accumulating evidence has revealed the significance of ICD-related genes in tumor progression and therapeutic response. In this study, we obtained two ICD-related clusters for glioblastoma (GBM) by applying consensus clustering, and further constructed a risk signature on account of the prognostic ICD genes. Based on the risk signature, we found that higher risk scores were associated with worse patient prognosis. Besides, the results illustrated that ferroptosis regulators/markers were highly enriched the high-risk group, and ferroptosis were correlated with cytokine signaling pathway and other immune-related pathways. We also discovered that high-risk scores were correlated to specific immune infiltration patterns and good response to immune checkpoint blockade (ICB) treatment. In conclusion, our study highlights the significance of ICD-related genes as prognostic biomarkers and immune response indicators in GBM. And the risk signature integrating prognostic genes possessed significant potential value to predict the prognosis of patients and the efficacy of ICB treatment.

27 April 2022 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
WRWeigang Ren
Weigang Ren
JRJiannan Ren
Jiannan Ren
NZNaiwen Zhang
Naiwen Zhang
XLXinlin Liu
Xinlin Liu
YDYao Deng
Yao Deng
HYHaixin Yu
Haixin Yu

1 January 2024 in Research
Verified
Journal Article
Open access
YZYajie Zhao
Yajie Zhao
XYXiaoqin Yin
Xiaoqin Yin
MZMing Zhou
Ming Zhou
WRWanqian Rao
Wanqian Rao
XJXuan Ji
Xuan Ji
SHShuo Hu
Shuo Hu
While the expression of programmed death ligand-1 (PD-L1) is associated with response to immune therapy, PD-L1-negative patients may still benefit from immune treatment. Programmed death ligand-2 (PD-L2), another crucial immune checkpoint molecule interacting with PD-1, correlates with the efficacy of various tumor immune therapies. This study investigates the expression of PD-L2 in non-small cell lung cancer (NSCLC) patients following anti-PD-1 therapy and its predictive value for clinical survival outcomes. Additionally, we explore the noninvasive, real-time, and dynamic quantitative analysis potential of PD-L2 positron emission tomography (PET) imaging in transplanted tumors. We utilized [ 68 Ga]Ga-labeled peptide HN11-1 for PD-L2 PET imaging. The results indicate a higher response rate to anti-PD-1 therapy in patients positive for both PD-L1 and PD-L2, with PD-L2 status independently predicting progression-free survival (PFS) with pembrolizumab treatment. Furthermore, [ 68 Ga]Ga-HN11-1 PET imaging demonstrates specificity in assessing PD-L2 status. Overall, we confirm the correlation between high PD-L2 expression and favorable PFS in NSCLC patients post anti-PD-1 therapy and highlight the promising potential of [ 68 Ga]Ga-HN11-1 as a specific tracer for PD-L2 in preclinical and initial human trials.

Verified
Journal Article
Open access
PDF file
WZWolong Zhou
Wolong Zhou
YCYuan-Da Cheng
Yuan-Da Cheng
LLLinfeng Li
Linfeng Li
HZHeng Zhang
Heng Zhang
XLXizhe Li
Xizhe Li
JZJunjie Zhang
Junjie Zhang
Background: Although significant progress has been made in immunotherapy for lung adenocarcinoma (LUAD), there is an urgent need to identify effective indicators to screen patients who are suitable for immunotherapy. Systematically investigating the cuproptosis-related genes (CRGs) in LUAD may provide new ideas for patients’ immunotherapy stratification. Method: We comprehensively analyzed the landscape of 12 CRGs in a merged TCGA and GEO LUAD cohort. We investigated the associations between tumor microenvironment and immunophenotypes. We utilized a risk score to predict the prognosis and immunotherapy response for an individual patient. Additionally, we conducted CCK-8 experiments to evaluate the impact of DLGAP5 knockdown on A549 cell proliferation. Result: We utilized an integrative approach to analyze 12 CRGs and differentially expressed genes (DEGs) in LUAD samples, resulting in the identification of two distinct CRG clusters and two gene clusters. Based on these clusters, we generated immunophenotypes and observed that the inflamed phenotype had the most abundant immune infiltrations, while the desert phenotype showed the poorest immune infiltrations. We then developed a risk score model for individual patient prognosis and immunotherapy response prediction. Patients in the low-risk group had higher immune scores and ESTIMATE scores, indicating an active immune state with richer immune cell infiltrations and higher expression of immune checkpoint genes. Moreover, the low-risk group exhibited better immunotherapy response according to IPS, TIDE scores, and Imvigor210 cohort validation results. In addition, our in vitro wet experiments demonstrated that DLGAP5 knockdown could suppress the cell proliferation of A549. Conclusion: Novel cuproptosis molecular patterns reflected the distinct immunophenotypes in LUAD patients. The risk model might pave the way to stratify patients suitable for immunotherapy and predict immunotherapy response.